PACB
Income statement / Annual
Last year (2025), Pacific Biosciences of California Inc's total revenue was $160.01 M,
an increase of 3.89% from the previous year.
In 2025, Pacific Biosciences of California Inc's net income was -$546.38 M.
See Pacific Biosciences of California Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$160.01 M |
$154.01 M |
$200.52 M |
$128.30 M |
$130.51 M |
$78.89 M |
$90.89 M |
$78.63 M |
$93.47 M |
$90.71 M |
| Cost of Revenue |
$109.33 M
|
$116.73 M
|
$147.74 M
|
$79.27 M
|
$71.65 M
|
$46.33 M
|
$56.32 M
|
$53.53 M
|
$58.81 M
|
$46.55 M
|
| Gross Profit |
$50.67 M
|
$37.28 M
|
$52.78 M
|
$49.04 M
|
$58.86 M
|
$32.57 M
|
$34.58 M
|
$25.10 M
|
$34.66 M
|
$44.16 M
|
| Gross Profit Ratio |
0.32
|
0.24
|
0.26
|
0.38
|
0.45
|
0.41
|
0.38
|
0.32
|
0.37
|
0.49
|
| Research and Development Expenses |
$97.31 M
|
$134.92 M
|
$187.17 M
|
$193.00 M
|
$112.90 M
|
$64.15 M
|
$59.63 M
|
$62.59 M
|
$65.32 M
|
$67.62 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$63.49 M
|
$59.12 M
|
$47.79 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$141.49 M
|
$175.02 M
|
$169.82 M
|
$160.85 M
|
$124.12 M
|
$72.80 M
|
$75.49 M
|
$63.49 M
|
$59.12 M
|
$47.79 M
|
| Other Expenses |
$369.44 M
|
$201.66 M
|
$30.26 M
|
$2.38 M
|
$32.27 M
|
$0.00
|
$0.00
|
$848.00 K
|
$516.00 K
|
$103.00 K
|
| Operating Expenses |
$608.24 M
|
$511.60 M
|
$387.25 M
|
$356.23 M
|
$269.30 M
|
$136.95 M
|
$135.12 M
|
$126.08 M
|
$124.44 M
|
$115.40 M
|
| Cost And Expenses |
$717.57 M
|
$628.33 M
|
$534.99 M
|
$435.50 M
|
$340.95 M
|
$183.28 M
|
$191.44 M
|
$179.61 M
|
$183.25 M
|
$161.96 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$6.95 M
|
$13.41 M
|
$14.34 M
|
$14.69 M
|
$12.53 M
|
$267.00 K
|
$2.61 M
|
$2.42 M
|
$2.92 M
|
$3.23 M
|
| Depreciation & Amortization |
$504.91 M
|
$53.35 M
|
$32.69 M
|
$17.32 M
|
$11.59 M
|
$9.30 M
|
$9.95 M
|
$7.22 M
|
$8.44 M
|
$3.88 M
|
| EBITDA |
-$34.20 M |
-$242.77 M |
-$271.13 M |
-$282.24 M |
-$250.76 M |
$38.97 M |
-$71.58 M |
-$92.92 M |
-$80.83 M |
-$67.27 M |
| EBITDA Ratio |
-0.21
|
-1.58
|
-1.35
|
-2.2
|
-1.92
|
0.49
|
-0.79
|
-1.18
|
-0.86
|
-0.74
|
| Operating Income Ratio |
-3.48
|
-3.08
|
-1.67
|
-2.39
|
-1.61
|
-1.32
|
-1.11
|
-1.28
|
-0.96
|
-0.79
|
| Total Other Income/Expenses Net |
$11.50 M
|
$164.78 M
|
$16.31 M
|
-$7.05 M
|
-$64.44 M
|
$133.79 M
|
$16.41 M
|
-$1.58 M
|
-$2.41 M
|
-$3.13 M
|
| Income Before Tax |
-$546.06 M
|
-$309.54 M
|
-$318.16 M
|
-$314.25 M
|
-$274.87 M
|
$29.40 M
|
-$84.13 M
|
-$102.56 M
|
-$92.19 M
|
-$74.38 M
|
| Income Before Tax Ratio |
-3.41
|
-2.01
|
-1.59
|
-2.45
|
-2.11
|
0.37
|
-0.93
|
-1.3
|
-0.99
|
-0.82
|
| Income Tax Expense |
$318.00 K
|
$316.00 K
|
-$11.42 M
|
$0.00
|
-$93.65 M
|
$0.00
|
$0.00
|
$848.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$546.38 M
|
-$309.85 M
|
-$306.74 M
|
-$314.25 M
|
-$181.22 M
|
$29.40 M
|
-$84.13 M
|
-$102.56 M
|
-$92.19 M
|
-$74.38 M
|
| Net Income Ratio |
-3.41
|
-2.01
|
-1.53
|
-2.45
|
-1.39
|
0.37
|
-0.93
|
-1.3
|
-0.99
|
-0.82
|
| EPS |
-1.82 |
-1.13 |
-1.21 |
-1.4 |
-0.89 |
0.18 |
-0.51 |
-0.76 |
-0.87 |
-0.83 |
| EPS Diluted |
-1.82 |
-1.07 |
-1.21 |
-1.4 |
-0.89 |
0.17 |
-0.51 |
-0.76 |
-0.87 |
-0.83 |
| Weighted Average Shares Out |
$299.96 M
|
$274.49 M
|
$253.63 M
|
$224.55 M
|
$203.62 M
|
$165.19 M
|
$152.53 M
|
$134.95 M
|
$105.68 M
|
$89.15 M
|
| Weighted Average Shares Out Diluted |
$299.96 M
|
$288.37 M
|
$253.63 M
|
$224.55 M
|
$204.14 M
|
$174.97 M
|
$152.53 M
|
$135.09 M
|
$105.68 M
|
$89.15 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
